The human 5-HT7 serotonin receptor splice variants: constitutive activity and inverse agonist effects

British Journal of Pharmacology
Kurt A Krobert, Finn O Levy

Abstract

1. Using membranes from stably or transiently transfected HEK293 cells cultured in 5-HT-free medium and expressing the recombinant human 5-HT(7) receptor splice variants (h5-HT(7(a)), h5-HT(7(b)) and h5-HT(7(d))), we compared their abilities to constitutively activate adenylyl cyclase (AC). 2. All h5-HT(7) splice variants elevated basal and forskolin-stimulated AC. The basal AC activity was reduced by the 5-HT(7) antagonist methiothepin and this effect was blocked by mesulergine (neutral 5-HT(7) antagonist) indicating that the inhibitory effect of methiothepin is inverse agonism at the 5-HT(7) receptor. 3. Receptor density correlated poorly with constitutive AC activity in stable clonal cell lines and transiently transfected cells. Mean constitutive AC activity as a percentage of forskolin-stimulated AC was significantly higher for the h5-HT(7(b)) splice variant compared to the h5-HT(7(a)) and h5-HT(7(d)) splice variants but only in stable cell lines. 4. All eight 5-HT antagonists tested inhibited constitutive AC activity of all splice variants in a concentration-dependent manner. No differences in inverse agonist potencies (pIC(50)) were observed between the splice variants. The rank order of potencies was in agreement and hig...Continue Reading

References

Apr 24, 1995·FEBS Letters·E S BursteinM R Brann
Apr 1, 1997·Trends in Pharmacological Sciences·R M EglenG R Martin
Sep 24, 1998·Trends in Pharmacological Sciences·P R SaxenaC M Villalón
Feb 9, 2000·Trends in Pharmacological Sciences·P VanhoenackerJ E Leysen
Apr 5, 2000·The Journal of Biological Chemistry·T BremnesH Attramadal
Mar 22, 2001·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·T Kenakin

❮ Previous
Next ❯

Citations

Jul 16, 2008·Naunyn-Schmiedeberg's Archives of Pharmacology·Suneet MehrotraAntoinette MaassenVanDenBrink
Sep 4, 2009·Naunyn-Schmiedeberg's Archives of Pharmacology·Benoit LabonteGabriella Gobbi
Sep 18, 2013·Experimental Brain Research·Evelien GellynckKathleen Van Craenenbroeck
Mar 23, 2004·European Journal of Pharmacology·Peter B HedlundPascal Bonaventure
Sep 11, 2008·The Journal of Biological Chemistry·Vaibhav P Pai, Nelson D Horseman
Jan 22, 2004·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Isabelle Gautherot, Regís Sodoyer
Jan 17, 2003·Proceedings of the National Academy of Sciences of the United States of America·P B HedlundJ G Sutcliffe
Mar 23, 2011·Molecular Neurobiology·Anne MatthysPeter Vanhoenacker
Apr 9, 2005·Current Eye Research·Koen BousseryJohan Van de Voorde
Jan 30, 2013·Biochemical Society Transactions·Nataliya Gorinski, Evgeni Ponimaskin
Jan 17, 2012·Cellular Signalling·Anne MatthysPeter Vanhoenacker
Nov 11, 2014·Annual Review of Animal Biosciences·Nelson D Horseman, Robert J Collier
Nov 24, 2004·Trends in Pharmacological Sciences·Peter B Hedlund, J Gregor Sutcliffe
Mar 11, 2016·PloS One·Martilias S FarrellBryan L Roth
Oct 6, 2005·Brain Research·Stephan VerleysdonkBernd Hamprecht
Sep 2, 2004·British Journal of Pharmacology·Pieter JanssenRomain A Lefebvre
Nov 23, 2006·The Journal of Craniofacial Surgery·Francesco CarinciFurio Pezzetti
Jul 26, 2007·The European Journal of Neuroscience·Sameera DasariRobin L Cooper
Feb 18, 2005·The Journal of Pharmacology and Experimental Therapeutics·Chris R GuthrieMark W Hamblin
Oct 29, 2017·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Kjetil Wessel AndressenFinn Olav Levy
Apr 30, 2017·Molecular Neurobiology·Grzegorz SatałaAndrzej J Bojarski
Jun 19, 2019·Journal of Psychopharmacology·Eva LatorreLorna W Harries
Dec 31, 2005·The Journal of Pharmacology and Experimental Therapeutics·Melissa A MahgoubLisa M Monteggia
Dec 7, 2018·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Andrea Hembre UlsundK W Andressen
Jan 21, 2020·Neuropharmacology·Philippe De DeurwaerdèreGiuseppe Di Giovanni
Sep 19, 2019·European Journal of Medicinal Chemistry·Giuseppe RomeoMaria Nunziata Modica
Oct 4, 2019·European Journal of Medicinal Chemistry·Sangeetha-Laura ThirumaranChristophe Rochais
Nov 2, 2019·Neuropharmacology·Elina T L'EstradeMatthias M Herth
Aug 26, 2020·Progress in Neurobiology·Josephine LabusEvgeni Ponimaskin

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here